Larsucosteral shows ‘promising efficacy signals’ for alcohol-associated hepatitis

Larsucosteral was well-tolerated and improved short-term biomarkers of liver injury or disease in a subset of patients with moderate to severe alcohol-associated hepatitis, according to research in The American Journal of Gastroenterology.“Alcohol-associated hepatitis (AH) is a severe form of liver disease with very high morbidity and mortality,” Craig J. McClain, MD, FACN, AGAF, FACG, FAASLD, director of the University of Louisville Alcohol Research Center and Hepatobiliary and Toxicology Center and professor of medicine, pharmacology and toxicology, told Healio. “DeathsRead More